insights_auto
Why is ALCOX down 2.10%?
Dive Deeperchevron_right
ALCOX:EPA
NicOx SA
€0.30
arrow_downward
-2.10%(-0.0065) 1D
Oct 12, 5:35:10 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALCOX...
Open
€0.31
High
€0.31
Low
€0.30
Mkt. cap
34.60M
Avg. vol.
164.58K
Volume
116.36K
52-wk high
€0.57
52-wk low
€0.28
EPS
-€0.03
Shares outstanding
97.55M
No. of employees
10
Open
€0.31
High
€0.31
Low
€0.30
Mkt. cap
34.60M
Avg. vol.
164.58K
Volume
116.36K
52-wk high
€0.57
52-wk low
€0.28
EPS
-€0.03
Shares outstanding
97.55M
No. of employees
10
News stories
From web sources and news partners
CNBC
·
1 hour ago
Jim Cramer says the bull market's remarkable 4-year run offers a crucial lesson for investors
New York Post
·
1 hour ago
NYSE's opening bell honors Italian Americans who beat stereotypes to reach pinnacle of finance
Simply Wall Street
·
27 minutes ago
What Does Microsoft (MSFT) Gain From Its New Maia 300 AI Chip?
Reuters
·
18 minutes ago
Nasdaq ends lower as oil prices surge ahead of earnings, economic data
Profile
Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health. Nicox is headquartered in Sophia Antipolis, France, and its Chairman and CEO is Michele Garufi.
Nicox is listed on Euronext Paris and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three programs in development, and it has two U.S. Food and Drug Administration approved products. Wikipedia
About NicOx SA
CEO-
Employees10
Founded1996
HeadquartersValbonne, Provence-Alpes-Côte d'Azur, France
SectorBiotechnology
Websitenicox.com